Seattle Children's Research Institute and Department of Pediatrics, University of Washington, Seattle, Washington.
Ther Clin Risk Manag. 2010 Feb 2;6:1-10. doi: 10.1057/rm.2009.17.
Antibody deficiency is the most frequently encountered primary immunodeficiency disease (PIDD) and patients who lack the ability to make functional immunoglobulin require life-long replacement therapy to prevent serious bacterial infections. Human serum immunoglobulin manufactured from pools of donated plasma can be administered intramuscularly, intravenously or subcutaneously. With the advent of well-tolerated preparations of intravenous immunoglobulin (IVIg) in the 1980s, the suboptimal painful intramuscular route of administration is no longer used. However, some patients continued to experience unacceptable adverse reactions to the intravenous preparations, and for others, vascular access remained problematic. Subcutaneously administered immunoglobulin (SCIg) provided an alternative delivery method to patients experiencing difficulties with IVIg. By 2006, immunoglobulin preparations designed exclusively for subcutaneous administration became available. They are therapeutically equivalent to intravenous preparations and offer patients the additional flexibility for the self-administration of their product at home. SCIg as replacement therapy for patients with primary antibody deficiencies is a safe and efficacious method to prevent serious bacterial infections, while maximizing patient satisfaction and improving quality of life.
抗体缺陷是最常见的原发性免疫缺陷病（PIDD），缺乏产生功能性免疫球蛋白能力的患者需要终身替代治疗以预防严重细菌感染。从捐赠的血浆中制成的人血清免疫球蛋白可以肌肉内、静脉内或皮下给药。20 世纪 80 年代，出现了耐受良好的静脉内免疫球蛋白（IVIg）制剂，因此不再使用肌肉内给药这种效果欠佳且痛苦的途径。然而，一些患者仍对静脉内制剂出现不可接受的不良反应，而对其他人来说，血管通路仍是个问题。皮下给予免疫球蛋白（SCIg）为有困难接受 IVIg 的患者提供了替代给药方法。到 2006 年，专门用于皮下给药的免疫球蛋白制剂面世。它们在治疗上与静脉内制剂等效，为患者在家中自行给药提供了额外的灵活性。SCIg 作为原发性抗体缺陷患者的替代治疗方法，是预防严重细菌感染的安全且有效的方法，同时最大限度地提高患者满意度并改善生活质量。
